Cited by 1,771Melanoma and MAPK PathwaysCancer Cells and MetastasisColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Open access

Straussman, Ravid, Morikawa, Teppei, Shee, Kevin, Barzily-Rokni, Michal, Qian, Zhi Rong, Du, Jinyan, Davis, Ashli, Mongare, Margaret M., Gould, Joshua, Frederick, Dennie T., Cooper, Zachary A., Chapman, Paul B., Solit, David B., Ribas, Antoni, Lo, Roger S., Flaherty, Keith T., Ogino, Shuji, Wargo, Jennifer A., Golub, Todd R.·2012·Nature

DOI 10.1038/nature11183PMC PMC3711467

Open this paper in CoChat — free account

Abstract

Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs. We found that stroma-mediated resistance is common, particularly to targeted agents. We characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance. Proteomic analysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase (PI(3)K)–AKT signalling pathways, and immediate resistance to RAF inhibition. Immunohistochemistry experiments confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment. Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma. A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines. More generally, this study indicates that the systematic dissection of interactions between tumours and their micro-environment can uncover important mechanisms underlying drug resistance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature11183

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citation
Fibroblasts in cancer
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citation
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citation
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citation
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
Self-citation
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citation

Flagged first, then by citations

Show all 30 references

Sorted by citations

Items 701–800 of 1,001

Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors
Conway, J. R. W., Warren, S. C., & Timpson, P. (2017) · Methods · doi:10.1016/j.ymeth.2017.04.014 · Cited by 41
Functional profiling of microtumors to identify cancer associated fibroblast-derived drug targets
Horman, S. R., To, J., Lamb, J. R., Zoll, J., Leonetti, N. A., Tu, B. P., Moran, R., Newlin, R., Walker, J. R., & Orth, A. P. (2017) · Oncotarget · doi:10.18632/oncotarget.21915 · Cited by 44
A Multifunctional Micellar Nanoplatform with pH‐Triggered Cell Penetration and Nuclear Targeting for Effective Cancer Therapy and Inhibition to Lung Metastasis
Jing, Y., Xiong, X., Ming, Y., Zhao, J., Guo, X., Yang, G., & Zhou, S. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700974 · Cited by 44
Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors
Wang, J., Pollard, K., Calizo, A., & Pratilas, C. A. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1992 · Cited by 44
Chemoresistance, Cancer Stem Cells, and miRNA Influences: The Case for Neuroblastoma
Buhagiar, A., & Ayers, D. (2015) · Analytical Cellular Pathology · doi:10.1155/2015/150634 · Cited by 44
Effect of aerobic training on the host systemic milieu in patients with solid tumours: an exploratory correlative study
Glass, O., Inman, B. A., Broadwater, G., Courneya, K. S., Mackey, J. R., Goruk, S. D., Nelson, E. R., Jasper, J., Field, C. J., Bain, J. R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.662 · Cited by 43
Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit
Gagliato, D. D. M., Jardim, D. L. F., Falchook, G. S., Tang, C. Z., Zinner, R., Wheler, J. J., Jankú, F., Subbiah, V., Piha-Paul, S. A., Fu, S., et al. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.06.001 · Cited by 43
MEK-Dependent Negative Feedback Underlies BCR–ABL-Mediated Oncogene Addiction
Asmussen, J. K., Lasater, E. A., Tajon, C. A., Osés-Prieto, J. A., Jun, Y., Taylor, B. S., Burlingame, A. L., Craik, C. S., & Shah, N. P. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0235 · Cited by 40
High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
Paulsson, J., Rydén, L., Strell, C., Frings, O., Tobin, N. P., Fornander, T., Bergh, J. C. S., Landberg, G., Stål, O., & Östman, A. (2016) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.56 · Cited by 43
Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells
Niepel, M., Hafner, M. A., Chung, M., & Sorger, P. K. (2017) · Current Protocols in Chemical Biology · doi:10.1002/cpch.21 · Cited by 42
Virus-Induced Changes in mRNA Secondary Structure Uncover cis-Regulatory Elements that Directly Control Gene Expression
Mizrahi, O., Nachshon, A., Shitrit, A., Gelbart, I. A., Dobešová, M., Brenner, S., Kahana, C., & Stern‐Ginossar, N. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.09.003 · Cited by 42
The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment
Ma, B., Wells, A. H., & Clark, A. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.021 · Cited by 44
Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Gui, Y., Aguilar-Mahecha, A., Krzemień, U., Hosein, A., Buchanan, M., Lafleur, J., Pollak, M., Ferrario, C., & Basik, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1268 · Cited by 35
Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment
Peng, Y., Bariwal, J. B., Kumar, V., Tan, C., & Mahato, R. I. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900136 · Cited by 44
RTK Inhibitors in Melanoma: From Bench to Bedside
Sabbah, M., Najem, A., Krayem, M., Awada, A. H., Journé, F., & Ghanem, G. (2021) · Cancers · doi:10.3390/cancers13071685 · Cited by 46
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
Seip, K., Fleten, K. G., Barkovskaya, A., Nygaard, V., Haugen, M. H., Engesæter, B. Ø., Mælandsmo, G. M., & Prasmickaite, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7671 · Cited by 41
Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer
Pfeifer, M., Brammeld, J. S., Price, S., Pilling, J. E., Bhavsar, D., Farcas, A. M., Bateson, J., Sundarrajan, A., Miragaia, R. J., Guan, N., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06190-w · Cited by 43
Synergistic effect of lung tumor‐associated dendritic cell‐derived HB‐EGF and CXCL5 on cancer progression
Kuo, P., Huang, M., Hung, J., Chou, S., Chiang, S.-Y., Huang, Y., Yang, C., Tsai, M., Chang, W., & Hsu, Y. (2013) · International Journal of Cancer · doi:10.1002/ijc.28673 · Cited by 42
Role of phosphoproteomics in the development of personalized cancer therapies
Cutillas, P. R. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400104 · Cited by 42
Crosstalk Between Nuclear MET and SOX9/β-Catenin Correlates with Castration-Resistant Prostate Cancer
Xie, Y., Lu, W., Liu, S., Yang, Q., Carver, B. S., Li, E., Wang, Y. Z., Fazli, L., Gleave, M. E., & Chen, Z. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1078 · Cited by 43
Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications
de Bruin, E. C., Taylor, T., & Swanton, C. (2013) · Genome Medicine · doi:10.1186/gm505 · Cited by 44
Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function
Ott, P. A., & Bhardwaj, N. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00346 · Cited by 44
Cancer Secretomes and Their Place in Supplementing Other Hallmarks of Cancer
Patel, S. J., Wetie, A. G. N., Darie, C. C., & Clarkson, B. D. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-06068-2_20 · Cited by 42
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
Chen, F., Ishikawa, Y., Akashi, A., Naoe, T., & Kiyoi, H. (2016) · Oncotarget · doi:10.18632/oncotarget.10147 · Cited by 43
New tools for old drugs: Functional genetic screens to optimize current chemotherapy
Gerhards, N. M., & Rottenberg, S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.001 · Cited by 43
Mapping the Pathways of Resistance to Targeted Therapies
Wood, K. C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1248 · Cited by 41
Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
Corte, C. M. D., Fasano, M., Papaccio, F., Ciardiello, F., & Morgillo, F. (2014) · Biomedicines · doi:10.3390/biomedicines2040345 · Cited by 41
Hitting Them Where They Live: Targeting the Glioblastoma Perivascular Stem Cell Niche
Brooks, M. D., Sengupta, R., Snyder, S. C., & Rubin, J. B. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-013-0012-0 · Cited by 42
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway‐induced resistance to vascular endothelial growth factor receptor inhibitor
Nakagawa, T., Matsushima, T., Kawano, S., Nakazawa, Y., Kato, Y., Adachi, Y., Abe, T., Semba, T., Yokoi, A., Matsui, J., et al. (2014) · Cancer Science · doi:10.1111/cas.12409 · Cited by 41
Update on use of aldesleukin for treatment of high-risk metastatic melanoma
Wargo, J. A., Reuben, A., Cooper, Z. A., & Amaria, R. N. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s61590 · Cited by 42
Self-citation
MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure
Boccaccio, C., & Comoglio, P. M. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.09.008 · Cited by 42
Analysis of growth factor signaling in genetically diverse breast cancer lines
Niepel, M., Hafner, M. A., Pace, E. A., Chung, M., Chai, D. H., Zhou, L., Muhlich, J. L., Schoeberl, B., & Sorger, P. K. (2014) · BMC Biology · doi:10.1186/1741-7007-12-20 · Cited by 41
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy
Xie, Q. R., Su, Y., Dykema, K. J., Johnson, J. S., Koeman, J. M., Giorgi, V. D., Huang, A., Schlegel, R., Essenburg, C. J., Kang, L., et al. (2013) · Genes & Cancer · doi:10.1177/1947601913501075 · Cited by 41
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
Maverakis, E., Tran, K. A., Cheng, M., Mitra, A., Ogawa, H., Shi, V. Y., Olney, L. P., & Kloxin, A. M. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s93545 · Cited by 42
Impacts of Ionizing Radiation on the Different Compartments of the Tumor Microenvironment
Leroi, N., Lallemand, F., Coucke, P. A., Noël, A., & Martinive, P. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00078 · Cited by 41
Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors
Peacock, J. D., Pridgeon, M. G., Tovar, E. A., Essenburg, C. J., Bowman, M. J., Madaj, Z., Koeman, J. M., Boguslawski, E. A., Grit, J. L., Dodd, R. D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3167 · Cited by 41
Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
Swayden, M., Chhouri, H., Anouar, Y., & Grumolato, L. (2020) · Cells · doi:10.3390/cells9122601 · Cited by 47
Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer
Mouratidis, P., & ter Haar, G. (2022) · Cancers · doi:10.3390/cancers14030638 · Cited by 40
Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells
Hmada, Y. A., Brodell, R. T., Kharouf, N., Flanagan, T. W., AlAmodi, A. A., Hassan, S.-Y., Shalaby, H., Hassan, S.-L., Haïkel, Y., Megahed, M., et al. (2024) · Cancers · doi:10.3390/cancers16020470 · Cited by 44
Microenvironment-mediated resistance to anticancer therapies
Olson, O. C., & Joyce, J. A. (2012) · Cell Research · doi:10.1038/cr.2012.123 · Cited by 39
Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma
Hwang, S., Kim, H., Min, M. S., Raghunathan, R., Panova, I. P., Munshi, R., & Ryu, B. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.160 · Cited by 40
Proteomic profiling of the tumor microenvironment: recent insights and the search for biomarkers
Hanash, S., & Schliekelman, M. J. (2014) · Genome Medicine · doi:10.1186/gm529 · Cited by 40
The molecular composition of the metastatic niche
Descot, A., & Óskarsson, T. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.04.017 · Cited by 40
Chemotherapy-induced uridine diphosphate release promotes breast cancer metastasis through P2Y6 activation
Ma, X., Pan, X., Wei, Y., Tan, B., Yang, L., Ren, H., Qian, M., & Du, B. (2016) · Oncotarget · doi:10.18632/oncotarget.8664 · Cited by 40
Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling
Owusu, B. Y., Bansal, N., Venukadasula, P. K. M., Ross, L. J., Messick, T. E., Goel, S., Galemmo, R. A., & Klampfer, L. (2016) · Oncotarget · doi:10.18632/oncotarget.8785 · Cited by 40
Eruptive nevi associated with medications (ENAMs)
Perry, B. M., Nguyen, A., Desmond, B., Blattner, C. M., Thomas, R., & Young, R. J. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.04.064 · Cited by 40
Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
Ai, J., Chen, Y., Xia, P., Ji, Y., Xi, Y., Shen, Y., Yang, X., Su, Y., Sun, Y., Gao, Y., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0368 · Cited by 40
Tumor‐stroma interactions differentially alter drug sensitivity based on the origin of stromal cells
Landry, B. D., Leete, T., Richards, R., Cruz‐Gordillo, P., Schwartz, H. R., Honeywell, M. E., Ren, G., Schwartz, A. D., Peyton, S. R., & Lee, M. J. (2018) · Molecular Systems Biology · doi:10.15252/msb.20188322 · Cited by 39
Fibrous stroma: Driver and passenger in cancer development
Sharma, V., Letson, J., & Furuta, S. (2022) · Science Signaling · doi:10.1126/scisignal.abg3449 · Cited by 38
Modeling Signaling Networks to Advance New Cancer Therapies
Sáez-Rodríguez, J., MacNamara, A., & Cook, S. J. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104927 · Cited by 39
Overcoming Resistance to Targeted Therapies in Cancer
Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 39
BRAF inhibitors: From the laboratory to clinical trials
Rahman, M., Salajegheh, A., Smith, R. A., & Lam, A. K.-Y. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.008 · Cited by 39
Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology
Valcz, G., Sípos, F., Tulassay, Z., Molnar, B. A., & Yagi, Y. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202561 · Cited by 43
Resistance to Raf inhibition in cancer
Haarberg, H. E., & Smalley, K. S. M. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2013.12.004 · Cited by 40
Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis
Xing, W., Ai, J., Jin, S., Shi, Z., Xia, P., Wang, L., Ji, Y., Lu, D., Liu, Y., Geng, M., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.041 · Cited by 40
CUX1 modulates polarization of tumor-associated macrophages by antagonizing NF-κB signaling
Kühnemuth, B., Mühlberg, L., Schipper, M., Griesmann, H., Neeße, A., Milosevic, N., Wissniowski, T. T., Buchholz, M., Gress, T. M., & Michl, P. (2013) · Oncogene · doi:10.1038/onc.2013.530 · Cited by 39
Computation as the Mechanistic Bridge Between Precision Medicine and Systems Therapeutics
Hansen, J., & Iyengar, R. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.199 · Cited by 40
Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures
Drews‐Elger, K., Brinkman, J. A., Miller, P., Shah, S. H., Harrell, J. C., Silva, T. G. D., Ao, Z., Schlater, A., Azzam, D. J., Diehl, K. M., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2887-9 · Cited by 37
Combination of Vessel-Targeting Agents and Fractionated Radiation Therapy: The Role of the SDF-1/CXCR4 Pathway
Chen, G. T. Y., Fu, S., Yang, Y., Wang, C., Chiang, C., & Hong, J. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.036 · Cited by 39
Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer
Wu, J., Qin, H., Li, T., Cheng, K., Dong, J., Tian, M., Chai, N., Guo, H., Li, J., You, X. Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8287 · Cited by 39
Bidirectional cross talk between patient‐derived melanoma and cancer‐associated fibroblasts promotes invasion and proliferation
Izar, B., Joyce, C. E., Goff, S. L., Cho, N. L., Shah, P., Sharma, G., Li, J., Ibrahim, N., Gold, J. S., Hodi, F. S., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12513 · Cited by 39
Looking beyond the cancer cell for effective drug combinations
Dry, J. R., Yang, M., & Sáez-Rodríguez, J. (2016) · Genome Medicine · doi:10.1186/s13073-016-0379-8 · Cited by 38
Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH
Ruzzolini, J., Peppicelli, S., Andreucci, E., Bianchini, F., Margheri, F., Laurenzana, A., Fibbi, G., Pimpinelli, N., & Calorini, L. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.010 · Cited by 41
Activation of the sweet taste receptor, T1R3, by the artificial sweetener sucralose regulates the pulmonary endothelium
Harrington, E. O., Vang, A., Braza, J., Shil, A., & Chichger, H. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00490.2016 · Cited by 39
Quantitative proteomic profiling of primary cancer-associated fibroblasts in oesophageal adenocarcinoma
Manousopoulou, A., Hayden, A. L., Mellone, M., Garay‐Baquero, D. J., White, C., Noble, F., López, M. E. P., Thomas, G. J., Underwood, T., & Garbis, S. D. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0042-9 · Cited by 39
Activated gastric cancer-associated fibroblasts contribute to the malignant phenotype and 5-FU resistance via paracrine action in gastric cancer
Ma, Y., Zhu, J., Chen, S., Li, T., Ma, J., Guo, S., Hu, J., Yue, T., Zhang, J., Wang, P., et al. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0599-7 · Cited by 41
Human colorectal cancer-derived carcinoma associated fibroblasts promote CD44-mediated adhesion of colorectal cancer cells to endothelial cells by secretion of HGF
Zhang, R., Qi, F., Shao, S., Li, G., & Feng, Y. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0914-y · Cited by 39
Intimate communications within the tumor microenvironment: stromal factors function as an orchestra
Cheng, B., Yu, Q., & Wang, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-022-00894-z · Cited by 43
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Wilson, M. A., Zhao, F., Khare, S., Roszik, J., Woodman, S. E., D'Andrea, K. P., Wubbenhorst, B. S., Rimm, D. L., Kirkwood, J. M., Kluger, H. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1162 · Cited by 39
Self-citation
Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib
Cheng, H., Chang, Y., Zhang, L., Luo, J., Tu, Z., Lu, X., Zhang, Q., Lu, J., Ren, X., & Ding, K. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500007h · Cited by 39
PAX3 and ETS1 synergistically activate MET expression in melanoma cells
Kubic, J. D., Little, E. C., Lui, J. W., Iizuka, T., & Lang, D. (2014) · Oncogene · doi:10.1038/onc.2014.420 · Cited by 38
Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts
Paulitschke, V., Berger, W., Paulitschke, P., Hofstätter, E., Knapp, B., Dingelmaier‐Hovorka, R., Födinger, D., Jäger, W. R., Szekeres, T., Meshcheryakova, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0701 · Cited by 38
An HTS-Compatible 3D Colony Formation Assay to Identify Tumor-Specific Chemotherapeutics
Horman, S. R., To, J., & Orth, A. P. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113499405 · Cited by 39
BRAF-induced tumorigenesis is IKKα-dependent but NF-κB–independent
Margalef, P., Colomer, C., Villanueva, A., Montagut, C. O., Iglesias, M., Bellosillo, B., Salazar, R., Martínez‐Iniesta, M., Bigas, A., & Espinosa, L. (2015) · Science Signaling · doi:10.1126/scisignal.2005886 · Cited by 38
DNA methylation signal has a major role in the response of human breast cancer cells to the microenvironment
Mathot, P., Grandin, M., Devailly, G., Souazé, F., Cahais, V., Morán, S., Campone, M., Herceg, Z., Esteller, M., Juin, P. P., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.88 · Cited by 40
Generation of stable PDX derived cell lines using conditional reprogramming
Borodovsky, A., McQuiston, T. J., Stetson, D., Ahmed, A., Whitston, D., Zhang, J., Grondine, M. R., Lawson, D., Challberg, S. S., Zinda, M. J., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0745-1 · Cited by 38
New Insights into the Tumor Microenvironment Utilizing Protein Array Technology
Huang, W. J., Luo, S., Burgess, R., Yi, Y.-H., Huang, G., & Huang, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020559 · Cited by 38
Prostate cancer liver metastasis: Dormancy and resistance to therapy
Ma, B., Wells, A. H., Wei, L., & Zheng, J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.004 · Cited by 37
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers
Hofmann, M.-C. C., Kunnimalaiyaan, M., Wang, J. R., Busaidy, N. L., Sherman, S. I., Lai, S. Y., Zafereo, M., & Cabanillas, M. E. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0129 · Cited by 39
Prognostic Value of Tumor-microenvironment-associated Genes in Ovarian Cancer
Li, S., Yao, J., Zhang, S., Zhou, X., Zhao, X., Di, N., Hao, S., & Zhi, H. (2022) · BIO Integration · doi:10.15212/bioi-2022-0008 · Cited by 37
Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance
Tajaldini, M., Poorkhani, A., Amiriani, T., Amiriani, A., Javid, H., Aref, P., Ahmadi, F., Sadani, S., & Khori, V. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175991 · Cited by 38
The MAPK pathway as an apoptosis enhancer in melanoma
Haydn, J. M., Hufnagel, A., Grimm, J., Maurus, K., Schartl, M., & Meierjohann, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2079 · Cited by 39
New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
Luke, J. J., & Ott, P. A. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s39568 · Cited by 39
C-RAF Mutations Confer Resistance to RAF Inhibitors
Antony, R., Emery, C. M., Sawyer, A. M., & Garraway, L. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4089 · Cited by 39
Developing biomarkers to predict benefit from HGF / MET pathway inhibitors
Koeppen, H., Rost, S., & Yauch, R. L. (2013) · The Journal of Pathology · doi:10.1002/path.4268 · Cited by 37
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition
Comunanza, V., Corà, D., Orso, F., Consonni, F. M., Middonti, E., Nicolantonio, F. D., Buzdin, A. A., Sica, A., Médico, E., Sangiolo, D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505774 · Cited by 39
Small role with big impact: miRNAs as communicators in the cross-talk between cancer-associated fibroblasts and cancer cells
Wang, Z., Tan, Y., Yu, W., Zheng, S. S., Zhang, S., Sun, L., & Ding, K. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.17680 · Cited by 37
Integrating Models to Quantify Environment-Mediated Drug Resistance
Picco, N., Sahai, E. A., Maini, P. K., & Anderson, A. R. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0835 · Cited by 38
MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner
Andriani, F., Majorini, M. T., Mano, M., Landoni, E., Miceli, R., Facchinetti, F., Mensah, M., Fontanella, E., Dugo, M., Giacca, M., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0594-4 · Cited by 37
Proteomic identification of a marker signature for MAPKi resistance in melanoma
Paulitschke, V., Eichhoff, O. M., Gerner, C., Paulitschke, P., Bileck, A., Mohr, T. T., Cheng, P. F., Leitner, A., Guenova, E., Saulīte, I., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201695874 · Cited by 34
c-FOS drives reversible basal to squamous cell carcinoma transition
Kuonen, F., Li, N. Y., Haensel, D., Patel, T., Gaddam, S., Yerly, L., Rieger, K. E., Aasi, S. Z., & Oro, A. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109774 · Cited by 36
Modulating undruggable targets to overcome cancer therapy resistance
Passirani, C., Vessières, A., Regina, G. L., Link, W., & Silvestri, R. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100788 · Cited by 37
Destructive impact of t-lymphocytes, NK and mast cells on basal cell layers: implications for tumor invasion
Yuan, H., Hsiao, Y.-H., Zhang, Y., Wang, J., Yin, C., Shen, R., & Su, Y. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-258 · Cited by 37
Somatic alterations as the basis for resistance to targeted therapies
Blair, B. G., Bardelli, A., & Park, B. H. (2013) · The Journal of Pathology · doi:10.1002/path.4278 · Cited by 36
Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)
Grazia, G., Penna, I., Perotti, V., Anichini, A., & Tassi, E. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2491 · Cited by 38
Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
Yadav, V., Chen, S.-H., Yue, Y. G., Buchanan, S. G., Beckmann, R. P., & Peng, S.-B. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.003 · Cited by 36
Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas
Garandeau, D., Noujarède, J., Leclerc, J., Imbert, C., Garcia, V., Bats, M., Rambow, F., Gilhodes, J., Filleron, T., Meyer, N., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1141 · Cited by 41
Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities
Shah, K., & Rawal, R. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200103111539 · Cited by 36
Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies
Diazzi, S., Tartare‐Deckert, S., & Deckert, M. (2020) · Cancers · doi:10.3390/cancers12061364 · Cited by 44
Applications of Protein Microarrays in Biomarker Discovery for Autoimmune Diseases
Li, S., Song, G., Bai, Y., Song, N., Zhao, J., Liu, J., & Hu, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645632 · Cited by 41

Authors: Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., Cooper, Z. A., Chapman, P. B., Solit, D. B., Ribas, A., Lo, R. S., Flaherty, K. T., Ogino, S., Wargo, J. A., & Golub, T. R.
Affiliations: Broad Institute (US)
Dana-Farber Cancer Institute (US)
Massachusetts General Hospital (US)
Memorial Sloan Kettering Cancer Center (US)
University of California, Los Angeles (US)
Brigham and Women's Hospital (US)
Corresponding author: Golub, Todd R.
ORCID: Straussman, Ravid
Morikawa, Teppei
Shee, Kevin
Barzily-Rokni, Michal
Qian, Zhi Rong
Gould, Joshua
Frederick, Dennie T.
Cooper, Zachary A.
Chapman, Paul B.
Solit, David B.
Ribas, Antoni
Lo, Roger S.
Flaherty, Keith T.
Ogino, Shuji
Wargo, Jennifer A.
Golub, Todd R.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-07
Volume: 487
Issue: 7408
Pages: 500-504
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature11183
PMC: PMC3711467
OpenAlex: W2055624262
Semantic Scholar: d51bc0a1730710ad5e74705bff1a2f756c61fc28
Cited by: 1,771
References: 30
Citations by year: 2026: 51 · 2025: 48 · 2024: 68 · 2023: 93 · 2022: 98 · 2021: 102 · 2020: 114 · 2019: 115 · 2018: 138 · 2017: 150 · 2016: 154 · 2015: 172 · 2014: 215 · 2013: 196 · 2012: 53
FWCI: 82.21
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
eScholarship (California Digital Library) (submittedVersion)
Funders: Howard Hughes Medical Institute
National Cancer Institute (R01CA166480, U54CA112962, P50CA093683, UM1CA186709)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords: RAF inhibitors, vemurafenib, drug resistance, tumor microenvironment, stromal cells, hepatocyte growth factor, MAPK signaling, PI3K/Akt signaling, combination therapy, co-culture model, targeted therapy, non-specific immunity, cancer cell lines, proteomics, immunohistochemistry, immunofluorescence
MeSH terms: Vemurafenib, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Indoles, Melanoma, Mutation, Prognosis, Sulfonamides, Signal Transduction, Stromal Cells, Hepatocyte Growth Factor, Coculture Techniques, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Proteomics, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Molecular Targeted Therapy, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks